ValuEngine Upgrades Apyx Medical (NASDAQ:APYX) to “Strong-Buy”

ValuEngine upgraded shares of Apyx Medical (NASDAQ:APYX) from a buy rating to a strong-buy rating in a report released on Wednesday, ValuEngine reports.

Several other research firms have also issued reports on APYX. Zacks Investment Research lowered shares of Apyx Medical from a buy rating to a hold rating in a research note on Tuesday. Piper Jaffray Companies increased their target price on shares of Apyx Medical to $10.00 and gave the stock an overweight rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Apyx Medical has a consensus rating of Buy and an average target price of $8.94.

APYX traded up $0.06 during midday trading on Wednesday, hitting $8.37. 1,981 shares of the company’s stock traded hands, compared to its average volume of 76,445. The company has a market cap of $274.20 million, a PE ratio of -28.76 and a beta of 0.15. The stock’s fifty day simple moving average is $8.03 and its 200-day simple moving average is $7.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.73 and a quick ratio of 7.93. Apyx Medical has a one year low of $3.55 and a one year high of $8.89.

Apyx Medical (NASDAQ:APYX) last posted its earnings results on Monday, November 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.05. Apyx Medical had a negative net margin of 66.77% and a negative return on equity of 20.25%. The firm had revenue of $7.58 million during the quarter, compared to analysts’ expectations of $6.78 million. The firm’s revenue for the quarter was up 106.3% compared to the same quarter last year. On average, research analysts expect that Apyx Medical will post -0.6 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of APYX. BlackRock Inc. boosted its position in Apyx Medical by 372.5% during the second quarter. BlackRock Inc. now owns 2,123,214 shares of the company’s stock worth $14,268,000 after purchasing an additional 1,673,854 shares during the period. State Street Corp lifted its position in shares of Apyx Medical by 34.2% during the 3rd quarter. State Street Corp now owns 557,677 shares of the company’s stock worth $3,775,000 after purchasing an additional 142,098 shares during the last quarter. Calamos Advisors LLC acquired a new position in shares of Apyx Medical during the 4th quarter worth about $1,164,000. Bank of New York Mellon Corp boosted its stake in Apyx Medical by 388.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,587 shares of the company’s stock valued at $770,000 after purchasing an additional 91,133 shares during the period. Finally, Charles Schwab Investment Management Inc. bought a new stake in Apyx Medical during the 2nd quarter valued at approximately $524,000. Hedge funds and other institutional investors own 51.99% of the company’s stock.

About Apyx Medical

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.

See Also: Cost of Debt

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.